Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Sarcoma 1Recurrence 1Precancerous Conditions 1Pharyngeal Neoplasms 1Peritoneal Neoplasms 1Paranasal Sinus Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Glioblastoma 1Colonic Neoplasms 1Breast Neoplasms 1Biomarker Change Linked to Breast Cancer 1

Interventions

pembrolizumab 1Erlotinib Hydrochloride 1Cryosurgery 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pharyngeal Neoplasms × Celecoxib × Clear all
NCT00970502 2017-04-10

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
15 enrolled 16 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡